Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Editorial
. 2022 Aug 31;12(9):1425.
doi: 10.3390/jpm12091425.

White Blood Cells, COVID-19, and Mendelian Randomization

Cristian Baicus  1   2   3
Affiliations
Editorial

White Blood Cells, COVID-19, and Mendelian Randomization

Cristian Baicus. J Pers Med. .

Abstract

Many observational studies have shown an association between the severity of COVID-19 and the different white blood cell counts, most frequently neutrophils, lymphocytes, and eosinophils. The studies aimed to predict the prognosis, and therefore, a causal relationship was unnecessary. However, if we begin to look at these biomarkers as potential therapeutic targets, then causality is essential. Observational studies cannot prove a causal relationship, and randomized trials are not always feasible. In this case, Mendelian randomization studies, considered more valid than observational studies, could add to the arguments for causality. Two Mendelian randomization studies tested for a causal relationship between the number of different white cell populations and COVID-19 severity, but their results are different; therefore, the problem of causality is not settled in this case.

Keywords: COVID-19; Mendelian randomization; white blood cells.

PubMed Disclaimer

Conflict of interest statement

The author declares no conflict of interest.

Similar articles

See all similar articles

Cited by

References

    1. Huang G., Kovalic A.J., Graber C.J. Prognostic Value of Leukocytosis and Lymphopenia for Coronavirus Disease Severity. Emerg. Infect. Dis. 2020;26:1839–1841. doi: 10.3201/eid2608.201160. - DOI - PMC - PubMed
    1. Stoichitoiu L.E., Pinte L., Balea M.I., Nedelcu V., Badea C., Baicus C. Anticoagulant protein S in COVID-19: Low activity, and associated with outcome. Rom. J. Intern. Med. 2020;58:251–258. doi: 10.2478/rjim-2020-0024. - DOI - PubMed
    1. Sarkar S., Khanna P., Singh A.K. The Impact of Neutrophil-Lymphocyte Count Ratio in COVID-19: A Systematic Review and Meta-Analysis. J. Intensive Care Med. 2022;37:857–869. doi: 10.1177/08850666211045626. - DOI - PMC - PubMed
    1. Karakonstantis S., Gryllou N., Papazoglou G., Lydakis C. Eosinophil count (EC) as a diagnostic and prognostic marker for infection in the internal medicine department setting. Rom. J. Intern. Med. 2019;57:166–174. doi: 10.2478/rjim-2018-0039. - DOI - PubMed
    1. Liu K., Yang T., Peng X.F., Lv S.M., Ye X.L., Zhao T.S., Li J.C., Shao Z.J., Lu Q.B., Li J.Y., et al. A systematic meta-analysis of immune signatures in patients with COVID-19. Rev. Med. Virol. 2021;31:e2195. doi: 10.1002/rmv.2195. - DOI - PMC - PubMed

Publication types

LinkOut - more resources